2181-PUB: The Patient Characteristics of Contour Diabetes App Users Worldwide

Abstract

Since 2016 more than 600,000 people have been utilizing the CONTOUR®DIABETES app (CDA) in combination with connected CONTOUR® Blood Glucose Monitoring Systems (BGMSs) worldwide. The aim of this analysis was to assess demographic data of CDA users from North America (NA) 42.6%, Europe (EU) 47.9% and Asian Pacific (APAC) region 4.5%. We examined the CDA database of patients that uploaded at least one blood glucose (BG) result during September 2019. BG results were automatically synched from a BGMS to CDA via BLE (Bluetooth Low Energy) or had the capability to enter manually in the app. All other data were self-reported and included age, gender, diabetes type, therapy mode, physical activities, carbs and location. From 625,837 users 19.9% of patients recorded at least one BG result during September 2019. In all three regions the proportion of patients above 60 years old was similar (NA 26.6%, EU 23.8%, APAC 26.5%). There were slightly fewer male users in U.S. than in EU and APAC (NA 49.3%, EU 52.6%, APAC 52.8%). The proportion of T1D and T2D users was as follows in NA: T1D 12.9%, T2D 48.6%, EU :T1D 23.2%, T2D 39.4% and APAC: T1D 15.9%, T2D 48.9%. Analysis of treatment mode demonstrated that T2D patients treated by insulin alone or in combination with other glucose lowering medications (OAM) differed from region to region (NA 28.0%, EU 38.1%, APAC 14.5%). Among them daily BG testing adherence also varied (NA 25.5%, EU 33.3%, APAC 23.9%). The daily BG testing in T1D patients was also different per region (NA 30.3%, EU 33.8%, APAC 26.3%). Around 20% of patients that registered with CDA since 2016 were actively using the app. The majority of them were T2D patients across all regions. The proportion of insulin use in this population varied by region. This analysis showed that real world BG testing frequency in T2D patients treated with insulin alone or in combination with OAM as well as in T1D patients appears lower than current recommendations. Further analysis is planned to identify the profile of patients who would mostly benefit from the use of CDA. Disclosure J.M. Richardson: Employee; Self; Ascensia Diabetes Care. Employee; Spouse/Partner; Ascensia Diabetes Care. S. Pardo: Employee; Self; Ascensia Diabetes Care. R. Shaginian: Employee; Self; Ascensia Diabetes Care.